The Janus kinase inhibitor tofacitinib has demonstrated a consistent safety profile and sustained efficacy in rheumatoid arthritis patients over a maximum follow-up of 9.5 years, report the ORAL Sequel investigators.
A meta-analysis of 72 randomized controlled trials including 26,424 participants with knee osteoarthritis suggests that the beneficial pain-relief effects of oral NSAIDs peak at 2 weeks, while minor adverse events begin to appear at 4 weeks.
Individuals with rheumatoid arthritis (RA) and chronic obstructive pulmonary disease who are treated with abatacept do not have an elevated risk for adverse respiratory events relative to those given other biologics, real-world study results suggest.
Tocilizumab is associated with a lower risk for major adverse cardiovascular events than tumor necrosis factor inhibitors among patients with rheumatoid arthritis, whereas the use of conventional DMARDs may be linked to an elevated risk, researchers report.
Adding sarilumab to methotrexate significantly improves the signs and symptoms of rheumatoid arthritis relative to placebo in Japanese patients with an inadequate response to methotrexate monotherapy, study findings indicate.
Treatment with biologics in combination with conventional DMARDs is associated with a reduction in the duration of protective immunity induced by the 17DD yellow fever vaccine among patients with rheumatoid arthritis, research suggests.
Findings from a proof-of-concept study suggest that deep learning models based on electronic health records may be a feasible approach for forecasting disease outcomes in people with rheumatoid arthritis.
Progressive skin fibrosis is significantly associated with worsening lung function and an increased risk for death among patients with diffuse cutaneous systemic sclerosis, an analysis of EUSTAR data shows.
Findings from a systematic review and meta-analysis suggest that nearly half of patients with rheumatoid arthritis in remission experience disease relapse after elective discontinuation of tumor necrosis factor inhibitors.